Becton Dickinson & Co (BDX) Stock Analysis and Metrics

Sector: Healthcare Industry: Medical Instruments & Supplies CIK: 0000010795

Market Cap 44.07 Bn

P/E 25.25

P/S 2.01

Div. Yield 0.03

ROIC (Qtr) 0.09

Total Debt (Qtr) 19.54 Bn

Revenue Growth (1y) (Qtr) 1.63

Add ratio to table...

About

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that specializes in the development, manufacture, and sale of a broad range of medical supplies, devices, laboratory equipment, and diagnostic products. The company's offerings are used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. BD is a leading player in the medical technology industry, with a diverse portfolio of products and services that cater to various...

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that specializes in the development, manufacture, and sale of a broad range of medical supplies, devices, laboratory equipment, and diagnostic products. The company's offerings are used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. BD is a leading player in the medical technology industry, with a diverse portfolio of products and services that cater to various markets and customer segments.

The company's main business activities are categorized into three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces a range of medical technologies and devices that are used to improve healthcare delivery in various settings. This segment's products include medication delivery solutions, medication management solutions, and pharmaceutical systems. The primary customers served by BD Medical are hospitals and clinics, physicians, office practices, consumers and retail pharmacies, governmental and nonprofit public health agencies, pharmaceutical companies, and healthcare workers.

The BD Life Sciences segment provides products for the safe collection and transport of diagnostic specimens, and instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections, and cancers. This segment's products are used by hospitals, laboratories, and clinics, as well as by blood banks, healthcare workers, physicians, office practices, retail pharmacies, academic and government institutions, and pharmaceutical and biotechnology companies.

The BD Interventional segment provides vascular, urology, oncology, and surgical specialty products that are intended to be used once and then discarded or are either temporarily or permanently implanted. This segment's products are used by hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via the company's Homecare business.

BD competes in a highly competitive industry, with companies of varying sizes competing in the global medical technology field. The company competes on the basis of many factors, including price, quality, innovation, service, reputation, distribution, and promotion. To remain competitive, BD invests in research and development, quality management, quality improvement, product innovation, manufacturing, and supply chain.

The company's products are marketed and distributed in the United States and internationally through independent distribution channels, as well as directly to hospitals and other healthcare-related institutions by BD and independent sales representatives. BD also collaborates with universities, medical centers, and other entities on research and development programs and retains individual consultants and partners to support its efforts in specialized fields.

BD is subject to various federal and state laws, and laws outside the United States, concerning healthcare fraud and abuse, global anti-corruption, transportation, safety and health, and customs and exports. The company is also subject to regulation by the U.S. Food and Drug Administration (FDA) and various other federal and state agencies, as well as by foreign governmental agencies. BD actively maintains quality systems that establish standards for its product design, manufacturing, and distribution processes, in accordance with ISO standards and FDA regulation.

In recent years, BD has faced several regulatory issues, including a consent decree with the FDA related to its infusion pump products, a Warning Letter from the FDA with respect to its former BD Preanalytical Systems unit, and a Form 483 Notice from the FDA with respect to its Medication Management Systems facility. The company has worked to address these issues and has implemented corrective actions to ensure compliance with regulatory requirements.

BD is a global company with a diverse workforce of approximately 73,000 associates located in over 62 countries. The company is committed to attracting, developing, and retaining talented people in all different functions. BD's ability to recruit and retain such talent depends on several factors, including compensation and benefits, talent development and career opportunities, and its unique culture. To that end, the company continually invests in its associates to be an employer of choice.

In addition to its commitment to diversity, equity, and inclusion, BD is also committed to associate growth and development. The company holds itself and its associates accountable for learning and growing every day, which underscores its growth mindset culture. BD offers associates and managers a robust offering of tools to help in their personal and professional development, including career development plans, mentoring programs, and in-house learning opportunities.

BD is also committed to associate engagement. The company believes it is critical that its associates are informed, engaged, and can provide feedback. BD communicates frequently and transparently with its associates through a variety of communication methods, including video and written communications, town hall meetings, associate surveys, and its company intranet. The company also acknowledges individual contributions to BD through a number of rewards and recognition award programs.

Investment thesis

Bull case

The transition from a diversified medical device and life‑sciences conglomerate to a focused, high‑margin medtech platform creates a clear strategic narrative that the market is underestimating. The divestiture of the biosciences and diagnostics units, coupled with the $4 billion cash distribution, provides immediate liquidity and a disciplined capital allocation framework that prioritizes share repurchases and debt reduction. By shedding lower‑margin, high‑growth segments that required significant investment to scale, the company is now positioned to concentrate resources on its “fast‑growth, high‑margin” portfolio, which already includes AI‑driven connected care, pharmacy automation, biologics delivery and advanced tissue regeneration. This focus is expected to lift operating margins, improve free cash flow and enhance the ability to fund an accelerated product pipeline without diluting equity.
The Q1 earnings demonstrated robust operational execution, with a 53.4 % adjusted gross margin and a 21.2 % operating margin despite a 140‑basis‑point margin compression from tariffs. The company’s ability to offset tariff hits with productivity gains—an 8 % quarterly improvement—shows an effective lean manufacturing strategy that has already reduced the global plant network by roughly half. Such efficiencies increase resilience to supply‑chain shocks and provide a cost advantage in a market increasingly sensitive to price competition. When combined with a strong free‑cash‑flow conversion of 66 %, the company can sustain high-quality capital returns and potentially accelerate R&D or opportunistic M&A.
The innovation pipeline is a hidden catalyst that management has only lightly highlighted, yet it underpins several high‑impact product launches within the next 12–18 months. New devices such as Avatene Flowable, SurgiFor, HemoSphere Stream and the upcoming SurgiFore Pulse target emerging markets—biosurgery, wound irrigation and advanced hemostasis—each worth hundreds of millions in untapped revenue potential. These launches are supported by an accelerated development timeline, with some projects achieving 6‑12 month time‑to‑market reductions through targeted R&D Kaizens. When fully commercialized, these products will diversify revenue streams beyond consumables, improving the company’s risk profile against a single‑segment downturn.
Connected care and pharmacy automation are high‑margin growth engines that are already showing double‑digit revenue expansion, with APM and pharmacy automation each achieving high single‑digit and double‑digit growth, respectively. The company’s strategic investments—$30 million in incremental sales efforts and expanded sales forces in APM, PI, and VDB—signal a concerted push to capture additional market share in these mature yet evolving categories. These efforts are supported by a robust data ecosystem that ties device usage to clinical outcomes, thereby justifying price premiums and strengthening customer lock‑in. The momentum in these segments provides a structural growth path that is likely to accelerate as the shift toward outpatient and home‑based care continues.
Biologics delivery remains a core strength that is well positioned to benefit from the rising prevalence of chronic disease and the growing pipeline of GLP‑1 therapeutics. The company’s portfolio now includes more than 80 novel and biosimilar GLP‑1 molecules contracted, giving it a broad geographic reach that spans the U.S., China, Europe, Latin America and Southeast Asia. Even as vaccine demand tapers, biologics will continue to grow, providing a reliable source of recurring consumables revenue. Coupled with the fact that GLP‑1 device sales are driven by high‑margin prescriptions, this segment represents a scalable, long‑term growth engine that will likely outpace other traditional medical device categories.

The transition from a diversified medical device and life‑sciences conglomerate to a focused, high‑margin medtech platform creates a clear strategic narrative that the market is underestimating. The divestiture of the biosciences and diagnostics units, coupled with the $4 billion cash distribution, provides immediate liquidity and a disciplined capital allocation framework that prioritizes share repurchases and debt reduction. By shedding lower‑margin, high‑growth segments that required significant investment to scale, the company is now positioned to concentrate resources on its “fast‑growth, high‑margin” portfolio, which already includes AI‑driven connected care, pharmacy automation, biologics delivery and advanced tissue regeneration. This focus is expected to lift operating margins, improve free cash flow and enhance the ability to fund an accelerated product pipeline without diluting equity.
The Q1 earnings demonstrated robust operational execution, with a 53.4 % adjusted gross margin and a 21.2 % operating margin despite a 140‑basis‑point margin compression from tariffs. The company’s ability to offset tariff hits with productivity gains—an 8 % quarterly improvement—shows an effective lean manufacturing strategy that has already reduced the global plant network by roughly half. Such efficiencies increase resilience to supply‑chain shocks and provide a cost advantage in a market increasingly sensitive to price competition. When combined with a strong free‑cash‑flow conversion of 66 %, the company can sustain high-quality capital returns and potentially accelerate R&D or opportunistic M&A.
The innovation pipeline is a hidden catalyst that management has only lightly highlighted, yet it underpins several high‑impact product launches within the next 12–18 months. New devices such as Avatene Flowable, SurgiFor, HemoSphere Stream and the upcoming SurgiFore Pulse target emerging markets—biosurgery, wound irrigation and advanced hemostasis—each worth hundreds of millions in untapped revenue potential. These launches are supported by an accelerated development timeline, with some projects achieving 6‑12 month time‑to‑market reductions through targeted R&D Kaizens. When fully commercialized, these products will diversify revenue streams beyond consumables, improving the company’s risk profile against a single‑segment downturn.
Connected care and pharmacy automation are high‑margin growth engines that are already showing double‑digit revenue expansion, with APM and pharmacy automation each achieving high single‑digit and double‑digit growth, respectively. The company’s strategic investments—$30 million in incremental sales efforts and expanded sales forces in APM, PI, and VDB—signal a concerted push to capture additional market share in these mature yet evolving categories. These efforts are supported by a robust data ecosystem that ties device usage to clinical outcomes, thereby justifying price premiums and strengthening customer lock‑in. The momentum in these segments provides a structural growth path that is likely to accelerate as the shift toward outpatient and home‑based care continues.
Biologics delivery remains a core strength that is well positioned to benefit from the rising prevalence of chronic disease and the growing pipeline of GLP‑1 therapeutics. The company’s portfolio now includes more than 80 novel and biosimilar GLP‑1 molecules contracted, giving it a broad geographic reach that spans the U.S., China, Europe, Latin America and Southeast Asia. Even as vaccine demand tapers, biologics will continue to grow, providing a reliable source of recurring consumables revenue. Coupled with the fact that GLP‑1 device sales are driven by high‑margin prescriptions, this segment represents a scalable, long‑term growth engine that will likely outpace other traditional medical device categories.

Bear case

The company’s earnings guidance has been cut by roughly 20 % from previous forecasts, largely due to ongoing headwinds in vaccines, China, and the Alaris infusion pump line. This downward revision reflects the reality that the company still faces significant cost pressures—tariffs, global supply‑chain constraints, and intense price competition— that erode gross and operating margins. While the company has managed to offset some of these impacts through productivity gains, the guidance signals a potential long‑term contraction in earnings growth that could pressure share price in the medium term. Investors should be wary of the cumulative effect of these headwinds, which may outweigh the upside from new product launches if the company cannot maintain the same margin trajectory.
The China market remains a significant source of volatility, with a 10 % portfolio of Alaris vaccines subject to a price‑based procurement (VBP) program that has not yet fully abated. Even though the company expects 80 % of its China portfolio to transition to VBP by fiscal 2026, the current price compression is eroding revenue and margin growth in a key growth region. The uncertainty around the timing of tariff reductions and the potential for further supply‑chain disruptions could exacerbate the headwind. As China accounts for a sizable share of overall revenue, any prolonged downturn in that market could create a cyclical drag that is difficult to mitigate with the company’s current strategy.
Alaris, despite approaching a 60 % market share, continues to experience declining growth due to an extensive multi‑year upgrade wave that was undertaken to remediate past product quality issues. The company’s remediation efforts have temporarily strained resources and diluted short‑term profitability. Even with a 100‑basis‑point share gain in the first quarter, the company’s revenue growth in the Alaris segment is still lagging, and the company has to sustain significant commercial investment to maintain its competitive position. As the company continues to compete in a market with strong incumbents and rapidly advancing technologies, any failure to sustain growth in this segment could pose a material risk to the company’s top line.
The heavy reliance on recurring consumables revenue—over 90 % of total revenue—poses a structural risk, as the consumable business is vulnerable to cost‑controlling initiatives from payers, insurers, and hospitals. While recurring revenue offers stability, it also makes the company sensitive to payer reforms and shifts toward bundled payment models that could compress margins. In addition, as competitors launch lower‑cost or more technologically advanced alternatives, the company may face pricing pressure that erodes its high‑margin profile. The lack of diversification into non‑recurring, high‑margin services or software solutions could limit the company’s ability to offset consumables volatility.
The company’s ambitious “tuck‑in” M&A strategy—while providing incremental growth—introduces integration risk and potential dilution of operating focus. The recent $4 billion transaction with Waters, while strategically clean, required a complex reverse Morris Trust structure that could strain management bandwidth. Future tuck‑ins, especially those that are opportunistic rather than synergistic, risk failing to deliver the projected accretive returns on revenue and EPS. Moreover, the company’s stated commitment to non‑dilutive M&A may limit its ability to pursue larger, transformational deals that could be necessary to keep pace with disruptive competitors.

The company’s earnings guidance has been cut by roughly 20 % from previous forecasts, largely due to ongoing headwinds in vaccines, China, and the Alaris infusion pump line. This downward revision reflects the reality that the company still faces significant cost pressures—tariffs, global supply‑chain constraints, and intense price competition— that erode gross and operating margins. While the company has managed to offset some of these impacts through productivity gains, the guidance signals a potential long‑term contraction in earnings growth that could pressure share price in the medium term. Investors should be wary of the cumulative effect of these headwinds, which may outweigh the upside from new product launches if the company cannot maintain the same margin trajectory.
The China market remains a significant source of volatility, with a 10 % portfolio of Alaris vaccines subject to a price‑based procurement (VBP) program that has not yet fully abated. Even though the company expects 80 % of its China portfolio to transition to VBP by fiscal 2026, the current price compression is eroding revenue and margin growth in a key growth region. The uncertainty around the timing of tariff reductions and the potential for further supply‑chain disruptions could exacerbate the headwind. As China accounts for a sizable share of overall revenue, any prolonged downturn in that market could create a cyclical drag that is difficult to mitigate with the company’s current strategy.
Alaris, despite approaching a 60 % market share, continues to experience declining growth due to an extensive multi‑year upgrade wave that was undertaken to remediate past product quality issues. The company’s remediation efforts have temporarily strained resources and diluted short‑term profitability. Even with a 100‑basis‑point share gain in the first quarter, the company’s revenue growth in the Alaris segment is still lagging, and the company has to sustain significant commercial investment to maintain its competitive position. As the company continues to compete in a market with strong incumbents and rapidly advancing technologies, any failure to sustain growth in this segment could pose a material risk to the company’s top line.
The heavy reliance on recurring consumables revenue—over 90 % of total revenue—poses a structural risk, as the consumable business is vulnerable to cost‑controlling initiatives from payers, insurers, and hospitals. While recurring revenue offers stability, it also makes the company sensitive to payer reforms and shifts toward bundled payment models that could compress margins. In addition, as competitors launch lower‑cost or more technologically advanced alternatives, the company may face pricing pressure that erodes its high‑margin profile. The lack of diversification into non‑recurring, high‑margin services or software solutions could limit the company’s ability to offset consumables volatility.
The company’s ambitious “tuck‑in” M&A strategy—while providing incremental growth—introduces integration risk and potential dilution of operating focus. The recent $4 billion transaction with Waters, while strategically clean, required a complex reverse Morris Trust structure that could strain management bandwidth. Future tuck‑ins, especially those that are opportunistic rather than synergistic, risk failing to deliver the projected accretive returns on revenue and EPS. Moreover, the company’s stated commitment to non‑dilutive M&A may limit its ability to pursue larger, transformational deals that could be necessary to keep pace with disruptive competitors.

Consolidation Items Breakdown of Revenue (2025)

Equity Components Breakdown of Revenue (2025)

Peer comparison

Companies in the Medical Instruments & Supplies

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ISRG	Intuitive Surgical Inc	160.71 Bn	56.57	15.97	-
2	BDX	Becton Dickinson & Co	44.07 Bn	25.25	2.01	19.54 Bn
3	ALC	Alcon Inc	36.32 Bn	37.03	3.52	4.74 Bn
4	RMD	Resmed Inc	32.65 Bn	22.09	6.05	0.26 Bn
5	HOLX	Hologic Inc	22.91 Bn	31.25	5.55	2.51 Bn
6	WST	West Pharmaceutical Services Inc	19.22 Bn	37.36	6.25	0.20 Bn
7	COO	Cooper Companies, Inc.	13.67 Bn	34.50	3.29	2.50 Bn
8	ALGN	Align Technology Inc	12.17 Bn	30.13	3.02	-

Research Tools

Becton Dickinson & Co (NYSE: BDX)

About

Investment thesis

Bull case

Bear case

Consolidation Items Breakdown of Revenue (2025)

Equity Components Breakdown of Revenue (2025)

Peer comparison

Research Tools

Becton Dickinson & Co (NYSE: BDX)

About

Investment thesis

Bull case

Bear case

Consolidation Items Breakdown of Revenue (2025)

Equity Components Breakdown of Revenue (2025)

Peer comparison

Create an account

Sign In

Reset Password